Methotrexate for polymyalgia rheumatica

The objective of this review is to assess the benefits and harms of methotrexate for patients with PMR in terms of the following major outcomes: disease relapse, sustained discontinuation of corticosteroids, time to disease remission, physical function, glucocorticoid-related adverse events, short term serious adverse effects, and withdrawals due to adverse events.

This is a protocol.